But even a WallStreet bull like Roeska must acknowledge areas where the company continues to struggle. In his report on Monday, the analyst noted those issues, stating: Management pointed to a ...
CVS Health's David Joyner is expected to address how he will better manage rising patient costs in the Medicare business than his predecessor when he tackles his first earnings call as CEO on ...
WallStreet doesn't always have a consensus about a stock, but it does here. 13 out of 17 analysts call it a buy, and the other four call it a hold. None of them expect the price to go down.